Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pre-Clinical Studies

Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts


We compared two protocols for the expansion of human mesenchymal stromal cells (hMSCs) starting from diagnostic samples of BM aspirates (2–5 ml) or using the remnants in the bag and filter at the end of the BM infusions. The protocols differed in the presence of either 10% fetal bovine serum (FBS) or 5% platelet lysate (PL). We obtained a significantly (P=0.02) better expansion with PL, obtaining a median 1010-fold compared to 198-fold with a selected batch of FBS and in fewer days (29.8 in PL versus 41.4 in FBS). Overall, we recovered a variable number from 54.8 × 106 to 365 × 106 hMSCs in PL versus a variable number from 2.7 × 106 to 31 × 106 in FBS. No difference could be found in terms of gross morphology, differentiation potential, surface markers and immunological properties (inhibition of allogeneic PHA response and mixed lymphocyte reaction) of cells expanded with PL or FBS. The preparations were found within the range of acceptability for all the quality control criteria. Due to the clinical grade nature of the PL and the reproducibility of separate preparations, we propose this method to obtain hMSCs even from minute amounts of BM cells.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4


  1. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Lurià EA et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2: 83–92.

    CAS  Google Scholar 

  2. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–398.

    Article  Google Scholar 

  3. Le Blanc K, Pittenger M . Mesenchymal stem cells: progress toward promise. Cytotherapy 2005; 7: 36–45.

    CAS  Article  Google Scholar 

  4. Korbling M, Estrov Z . Adult stem cells for tissue repair—a new therapeutic concept? N Engl J Med 2003; 349: 570–582.

    Article  Google Scholar 

  5. Chen SL, Fang WW, Ye F, Liu YH, Quian J, Shan SJ et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92–95.

    Article  Google Scholar 

  6. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441.

    Article  Google Scholar 

  7. Lee ST, Jang JH, Cheong JW, Kim JS, Meagm HY, Hahn JS et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118: 1128–1131.

    Article  Google Scholar 

  8. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–1397.

    Article  Google Scholar 

  9. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316.

    CAS  Article  Google Scholar 

  10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.

    CAS  Article  Google Scholar 

  11. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393–395.

    CAS  Article  PubMed  Google Scholar 

  12. Introna M, Barbui AM, Golay J, Rambaldi A . Innovative cell-based therapies in onco-hematology: what are the clinical facts? Haematologica 2004; 89: 1253–1260.

    Google Scholar 

  13. Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M et al. Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Eur J Haematol 2006; 76: 309–316.

    Article  Google Scholar 

  14. Koller MR, Maher RJ, Manchel I, Oxender M, Smith H . Alternatives to animal sera for human bone marrow cell expansion: human serum and serum-free media. J Hematother 1998; 7: 413–423.

    CAS  Article  Google Scholar 

  15. Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander AR . Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004; 32: 1212–1225.

    CAS  Article  Google Scholar 

  16. Muller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006; 8: 437–444.

    CAS  Article  Google Scholar 

  17. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228–236.

    CAS  Article  Google Scholar 

  18. Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007; 211: 121–130.

    CAS  Article  Google Scholar 

  19. Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7: 509–519.

    CAS  Article  Google Scholar 

Download references


The work was partially supported by the Italian Association for Cancer Research (AIRC), the ‘Associazione Italiana contro le Leucemie, linfomi e mieloma (AIL) Bergamo-Sezione Paolo Belli’ and by a generous personal donation from Dr EC.

Author information

Authors and Affiliations


Corresponding author

Correspondence to M Introna.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website (

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Capelli, C., Domenghini, M., Borleri, G. et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 40, 785–791 (2007).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • MSC
  • platelet lysate
  • bone marrow stromal cells

Further reading


Quick links